CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Authors :: Savona, Michael R.
Kolibaba, Kathryn
Conkling, Paul
Kingsley, Edwin C.
Becerra, Carlos
Morris, John
Rifkin, Robert M.
Laille, Eric
Kellerman, Amy
Ukrainskyj, Stacey M.
Dong, Qian
Skikne, Barry S.
Source :: Blood; December 2014, Vol. 124 Issue: 21 p4638-4638, 1p
Publication Year :: 2014
Abstract: Savona: Karyopharm: Consultancy, Equity Ownership; Celgene: Consultancy; Gilead: Consultancy; Incyte: Consultancy. Kolibaba:Celgene: Research Funding. Conkling:Celgene: Research Funding. Rifkin:Celgene: Scientific Advisory Board Other; Millennium/Takeda: Scientific Advisory Board, Scientific Advisory Board Other; Onyx/Amgen: Scientific Advisory Board, Scientific Advisory Board Other. Laille:Celgene: Employment, Equity Ownership. Kellerman:Celgene: Employment. Ukrainskyj:Celgene: Employment, Equity Ownership. Dong:Celgene: Employment. Skikne:Celgene: Employment, Equity Ownership.

Full Text Access

Tools